Relafen Antitrust Litigation

Summary of Case and Settlement:

Case No. 01-12239 (D. Mass.). On September 28, 2005, Judge William G. Young of the United States District Court for the District of Massachusetts granted final approval to a $75 million class action settlement for the benefit of consumers and third-party payors who paid for branded and generic versions of the arthritis medication Relafen. In certifying an exemplar class of end-payors, the court singled out our Firm as experienced and vigorous advocates. See In re Relafen Antitrust Litig., 221 F.R.D. 260, 273 (D. Mass. 2004). In the opinion granting final approval to the settlement, the court commented that “Class counsel here exceeded my expectations in these respects [i.e., experience, competence, and vigor] in every way.” In re Relafen Antitrust Litig., 231 F.R.D. 52, 85 (D. Mass. 2005); see also id. at 80 (“The Court has consistently noted the exceptional efforts of class counsel.”). The litigation has produced many significant decisions including: 286 F Supp. 2d 56 (D. Mass. 2003) (denying motion to dismiss); 346 F. Supp. 2d 349 (D. Mass. 2004) (denying defendant’s motion for summary judgment).

Contact Us

First Name
Last Name
E-mail
Phone
Case This Inquiry Relates To
Comments